Merdury Biopharmaceutical

Merdury Biopharmaceutical Quick Ratio

The Quick Ratio (Acid Test) of Merdury Biopharmaceutical (6932.TWO) as of Oct 24, 2026 is 0.82. In the previous year, Quick Ratio (Acid Test) was 0.02 — a change of 5,095.34% (higher).

Quick Ratio

0.82

YoY

5,095.34%

Last updated:

Quick Ratio (Acid Test) of Merdury Biopharmaceutical is 2025 0.82 . Quick Ratio (Acid Test) of Merdury Biopharmaceutical was 2024 0.02 . It decreases by 5,095.34% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp develops and manufactures pharmaceutical products including Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, and multi-ingredient antihypertensive drugs. The company utilizes its StackDose platform to create controllable time-dissolving tablets for instant or sustained drug release. Products are primarily sold in Taiwan and the United States, targeting markets for drugs that do not meet special medical needs, difficult generics, and second-class new drugs. The company's revenue comes from the sale of these pharmaceutical products to customers in both regions. The firm's StackDose technology enables the development of specialized drug formulations that control the timing of drug effectiveness, differentiating its product range. This focus on innovative delivery systems supports sales in the pharmaceutical markets of Taiwan and the U.S., where demand exists for advanced generic and specialty medications. The company's product portfolio aligns with its strategic focus on non-special medical need drugs and second-class new drugs. Merdury Biopharmaceutical Corp targets healthcare providers and pharmacies in Taiwan and the United States as its primary customers. The company's self-developed StackDose platform allows for the creation of unique drug delivery systems that are sold under the company's own product lines. Sales of Sildenafil, Metformin, Tadalafil, and other key products form the core of the company's revenue streams. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Quick Ratio (Acid Test) of Merdury Biopharmaceutical is 0.82 in 2025.

Quick Ratio (Acid Test) of Merdury Biopharmaceutical changed from 0.02 to 0.82, representing a 5,095.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical